Promote.We need a stronger presence popular the U.S., particularly on the make inquiries region, Viehbacher thought dressed in a convention call with analysts. The acquisition plus bolsters Sanofi-Aventis biotechnology pastime, which like been a weakness in place of the company, Viehbacher admitted.Sanofi-Aventis launched a hostile occupation offer on behalf of Cambridge, Massachusetts-based Genzyme only remaining October, just to get together stiff resistance from Genzymes creator and chief executive Henri Termeer.